" class="no-js "lang="en-US"> Pier Vincenzo Piazza - Medtech Alert
Friday, May 01, 2026

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Pier Vincenzo Piazza

Pier Vincenzo Piazza

About Pier Vincenzo Piazza

Related Story

Fundraising

 Aelis Farma Announces the Success of its Initial Public Offering and Raises Approximately €25 Million on Euronext Paris | Pharmtech Focus

Aelis Farma Announces the Success of its Initial Public Offering and Raises Approximately €25 Million on Euronext Paris

February 16 2022

Aelis Farma, a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases […]

Clinical Trials

 Aelis Farma Announces Good Results From its First Administration in Humans for AEF0217

Aelis Farma Announces Good Results From its First Administration in Humans for AEF0217, its First Drug Candidate for the Treatment of Cognitive Disorders in Down Syndrome

December 3 2021

AELIS FARMA, a biotechnology company specializing in the treatment of brain disorders, announces today that AEF0217 […]